Gemcitabine + Cisplatin + Durvalumab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bile Duct Cancer
Conditions
Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Metastatic Intrahepatic Cholangiocarcinoma
Trial Timeline
Feb 13, 2024 → Dec 1, 2027
NCT ID
NCT05655949About Gemcitabine + Cisplatin + Durvalumab
Gemcitabine + Cisplatin + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Bile Duct Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05655949. Target conditions include Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06440993 | Phase 2 | Recruiting |
| NCT05655949 | Phase 2 | Recruiting |
Competing Products
13 competing products in Bile Duct Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 77 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 52 |
| IL-10 | Merck | Phase 2 | 52 |
| aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil | Merck | Phase 2 | 52 |
| LJN452 + Placebo to LJN452 | Novartis | Phase 2 | 52 |
| Regorafenib | Bayer | Phase 2 | 49 |
| Gemcitabine + Cisplatin + Sorafenib | Bayer | Phase 2 | 49 |
| A3384 | Ipsen | Phase 2 | 49 |
| Cabozantinib | Exelixis | Phase 2 | 49 |
| Cholic acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| Cholbam | Mirum Pharmaceuticals | Pre-clinical | 20 |
| Cholic Acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| GM-CT-01 + 5-Fluorouracil | Galectin Therapeutics | Phase 2 | 44 |